Eris Lifesciences Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Amit Bakshi
Algemeen directeur
₹48.8m
Totale compensatie
| Percentage CEO-salaris | 35.9% |
| Dienstverband CEO | 17.8yrs |
| Eigendom CEO | 42.9% |
| Management gemiddelde ambtstermijn | 8.2yrs |
| Gemiddelde ambtstermijn bestuur | 4.1yrs |
Recente managementupdates
Recent updates
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹3b |
| Jun 30 2024 | n/a | n/a | ₹4b |
| Mar 31 2024 | ₹49m | ₹17m | ₹4b |
| Dec 31 2023 | n/a | n/a | ₹4b |
| Sep 30 2023 | n/a | n/a | ₹4b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹49m | ₹17m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹46m | ₹26m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹27m | ₹27m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹3b |
| Sep 30 2020 | n/a | n/a | ₹3b |
| Jun 30 2020 | n/a | n/a | ₹3b |
| Mar 31 2020 | ₹49m | ₹18m | ₹3b |
| Dec 31 2019 | n/a | n/a | ₹3b |
| Sep 30 2019 | n/a | n/a | ₹3b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹49m | ₹18m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹49m | ₹11m | ₹3b |
Compensatie versus markt: De totale vergoeding ($USD 580.05K ) Amit } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 471.41K ).
Compensatie versus inkomsten: De vergoeding van Amit is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Amit Bakshi (49 yo)
17.8yrs
Tenure
₹48,776,648
Compensatie
Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & MD | no data | ₹48.78m | 42.86% ₹ 78.6b | |
| Chief Financial Officer | 8.2yrs | ₹18.01m | geen gegevens | |
| Executive Director & COO | 3.5yrs | ₹44.85m | geen gegevens | |
| President of Sales & Marketing | no data | ₹22.05m | geen gegevens | |
| Executive Director | no data | ₹12.40m | 4.36% ₹ 8.0b | |
| Whole Time Director | no data | ₹6.99m | 3.28% ₹ 6.0b | |
| Senior Vice President | no data | ₹13.72m | geen gegevens | |
| Compliance Officer & Company Secretary | 8.2yrs | geen gegevens | geen gegevens | |
| President Medical | no data | ₹12.31m | geen gegevens | |
| Vice President | no data | ₹12.36m | geen gegevens | |
| Vice President | no data | ₹13.30m | geen gegevens | |
| Vice President | no data | ₹15.08m | geen gegevens |
8.2yrs
Gemiddelde duur
50yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ERIS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & MD | 17.8yrs | ₹48.78m | 42.86% ₹ 78.6b | |
| Executive Director & COO | 3.9yrs | ₹44.85m | geen gegevens | |
| Executive Director | 17.8yrs | ₹12.40m | 4.36% ₹ 8.0b | |
| Whole Time Director | 4.3yrs | ₹6.99m | 3.28% ₹ 6.0b | |
| Independent Non-Executive Director | 6.6yrs | ₹4.13m | geen gegevens | |
| Independent Non-Executive Director | 2.3yrs | ₹4.05m | geen gegevens | |
| Independent Non-Executive Director | 3.8yrs | ₹4.51m | geen gegevens | |
| Independent Non-Executive Director | 3.9yrs | ₹4.65m | geen gegevens |
4.1yrs
Gemiddelde duur
50yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ERIS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).